

Docket No. 0205-UTL-9
Serial No. 09/011,940

Patent

AMENDMENTS TO THE CLAIMS

This listing of the claims replaces all prior versions and listing of claims in the application.

Listing of Claims

Claims 1-40. (cancelled)

41. (previously presented) A method of enhancing metabolism of nutrients, comprising administering by a parenteral route to a non-diabetic patient in need of enhancing metabolism of nutrients a nutritively effective amount of one or more nutrients or any combination thereof and one or more insulintropic peptide or peptides, wherein said peptide or peptides is GLP-1, GLP-1 (7-34), GLP-1 (7-35), GLP-1 (7-36), GLP (7-37), the deletion sequences thereof, the natural and non-natural amino acid residue substitutes thereof, the C-terminus carboxamides thereof, the C-terminus esters thereof, the C-terminus ketones thereof, the N-terminus modifications thereof, or any mixture thereof.

42. (previously presented) A method of enhancing metabolism of nutrients, comprising administering by a parenteral route to a patient with a disturbed glucose metabolism, a surgery patient, a comatose patient, a patient in shock, a patient with gastrointestinal disease, a patient with digestive hormone disease, an obese patient, an atherosclerotic patient, a patient with vascular disease, a patient with gestational diabetes, a patient with liver disease, a patient with liver cirrhosis, a patient with glucocorticoid excess, a patient with Cushing's disease, a patient with activated counterregulatory hormones that occur after trauma or a disease, a patient with hypertriglyceridemia, or a patient with chronic pancreatitis, a nutritively effective amount of one or more nutrients or any combination thereof and one or more insulintropic peptides.

43. (previously presented) The method of claim 41, wherein said insulintropic peptide or peptides is GLP-1 (7-36) amide.

44. (previously presented) A method of enhancing metabolism of nutrients, comprising administering by a parenteral route to a patient in need of enhancing metabolism of nutrients a

Page 2 of 5

Docket No. 0205-UTL-9
Serial No. 09/011,940

Patent

nutritively effective amount of glucose and one or more insulintropic peptide or peptides, wherein said insulintropic peptide or peptides is GLP-1, GLP-1 (7-34), GLP-1 (7-35), GLP-1 (7-36), GLP (7-37), the deletion sequences thereof, the natural and non-natural amino acid residue substitutes thereof, the C-terminus carboxamides thereof, the C-terminus esters thereof, the C-terminus ketones thereof, the N-terminus modifications thereof, or any mixture thereof; wherein the administration of the nutrient(s) produces a blood glucose level in the patient of from about 80 to 180 mg glucose per deciliter of blood, and the rate of administration is calculated to deliver up to about 1000 g of glucose or its equivalent per patient per day.

Claims 45-47 (cancelled)

48. (previously presented) The method of claim 41 wherein said nutrient is one or more amino acids, lipids, free fatty acids, mono- or diglycerides or glycerol, or any combination thereof.

Claims 49-50 (cancelled)

51. (previously presented) A method for non-alimentary nutrition comprising administering by a parenteral route to a patient in need of parenteral nutrition, a nutritively effective amount of one or more nutrients selected from the group consisting of carbohydrates, amino acids, lipids, free fatty acids, mono- or diglycerides, glycerol and any combination thereof; and one or more insulintropic peptides, wherein the insulintropic peptide is GLP-1, wherein the administration of the nutrient(s) produces a blood glucose level in the patient of from about 80 to 180 mg glucose per deciliter of blood, and the rate of administration is calculated to deliver up to about 1000 g of glucose or its equivalent per patient per day.

Claims 52-54 (cancelled)

55. (Previously presented) The method of claim 41 wherein the insulintropic peptide is an exendin.